Table 4.
Baseline data for patients with and without sustained virological responses (by modified intention-to-treat analysis)
| Non-SVR12 (n = 11) | SVR12 (n = 315) | P value | |
| Age (yr) | 54.1 ± 13.5 | 51.8 ±11.9 | 0.098 |
| Gender (males, %) | 4 (36.4) | 162 (51.4)3 | 0.080 |
| TBil (µmol/L) | 20.16 ± 10.13 | 19.58 ± 10.69 | 0.184 |
| ALT (U/L) | 62.45 ± 53.85 | 52.28 ± 46.14 | 0.034 |
| AST (U/L) | 42.73 ± 30.30 | 47.29 ± 39.74 | 0.516 |
| Albumin (g/L) | 37.7 ± 10.0 | 39.6 ± 8.6 | 0.214 |
| TCHO (mmol/L) | 3.93 ± 0.59 | 3.85 ± 0.60 | 0.879 |
| Hemoglobin (mg/dL) | 119.1 ± 15.0 | 119.5 ± 23.8 | 0.497 |
| Platelets (109/L) | 165.6 ± 68.4 | 144.9 ± 76.0 | 0.167 |
| AFP (ng/mL) | 5.03 ± 4.49 | 4.77 ± 6.15 | 0.407 |
| Log10 HCV RNA (IU/mL) | 6.5 ± 0.6 | 6.5 ± 1.0 | 0.450 |
| Cirrhosis, n (%) | 5 (45.5) | 138 (43.8) | 0.621 |
| Treatment experienced, n (%) | 1 (9.1) | 49 (15.6) | 0.052 |
TBil: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TCHO: Total cholesterol; AFP: Alpha fetoprotein; HCV: Hepatitis C virus; SVR12: Sustained virological response at post-treatment week 12.